NCT02264639View on ClinicalTrials.gov

A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 23, 2015

Primary Completion Date

October 22, 2018

Study Completion Date

October 22, 2018

Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
DRUG

Pegcetacoplan

Complement (C3) Inhibitor

Trial Locations (7)

21231

John Hopkins Hospital, Baltimore

27710

Duke University Medical Center, Durham

33014

Lakes Research, Miami Lakes

40202

University of Lousiville, Louisville

44195

Cleveland Clinic, Cleveland

89135

Cure 4 The Kids Foundation, Las Vegas

90033

University of Southern California Norris Comprehensive Cancer Center, Los Angeles

Sponsors
All Listed Sponsors
lead

Apellis Pharmaceuticals, Inc.

INDUSTRY